Don Creighton


Inflation Reduction Act and the Impact on Pharmaceutical Pricing and Investment Decisions

November 25, 2022

The reference to “maximum fair price” in the act bodes poorly for manufacturers and suggests more of a take-it-or-leave-it situation rather than a negotiation where clinical evidence would be the prevailing factor in determining price.